Osteoporosis

Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis

Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis

By

Rates of incident clinical vertebral fracture, incident nonvertebral fracture, hip fracture, and clinical fractures decreased 6 months after initiation of teriparatide.

Genetic Screening May Predict Osteoporosis, Fracture Risk

Genetic Screening May Predict Osteoporosis, Fracture Risk

By

Genetic testing may identify individuals with an increased risk for osteoporosis and bone fracture.

One-Third of Canadian Patients Get Hip Fracture Repair Within 24 Hours

One-Third of Canadian Patients Get Hip Fracture Repair Within 24 Hours

Only one-third of Canadian patients received hip fracture repair surgery within the desired 24 hours.

HbA1c-Corrected FRAX Score May Better Predict Fracture Risk in Type 2 Diabetes

HbA1c-Corrected FRAX Score May Better Predict Fracture Risk in Type 2 Diabetes

By

A corrected HbA1c factor may improve the ability to predict the risk for fracture by the FRAX algorithm in T2D.

Decreased Osteoporosis Treatment Initiation Observed After Hip Fracture

Decreased Osteoporosis Treatment Initiation Observed After Hip Fracture

By

Researchers observed a reduction in subsequent nonvertebral fracture rates in patients who initiated osteoporosis treatment.

Effect of Mediterranean Diet Plus Vitamin D3 on Bone Density in Osteoporosis

Effect of Mediterranean Diet Plus Vitamin D3 on Bone Density in Osteoporosis

By

Investigators examined the effect of consuming a Mediterranean-style diet for 1 year on inflammatory response and bone health in the elderly.

Empagliflozin Does Not Increase Fracture Risk in Type 2 Diabetes

Empagliflozin Does Not Increase Fracture Risk in Type 2 Diabetes

By

The risk for bone fractures was not increased in patients with type 2 diabetes using empagliflozin compared with placebo or glimepiride.

New Romosozumab BLA Includes Data From Additional Osteoporosis Trials

New Romosozumab BLA Includes Data From Additional Osteoporosis Trials

By

The Biologics License Application has been resubmitted for Evenity, an investigational treatment for osteoporosis in postmenopausal women at high risk for fracture.

Romosozumab: Effective in Men With Osteoporosis

Romosozumab: Effective in Men With Osteoporosis

By

Romosozumab increased spine and hip bone mineral density after 12 months of treatment.

Treating Osteoporotic Pain: Expert Interview

Treating Osteoporotic Pain: Expert Interview

By

Pain resulting from osteoporotic fractures should be treated with a multimodal approach that includes pharmacological and nonpharmacological strategies.

Osteoporosis Fracture Risk Awareness Lacking in Postmenopausal Women

Osteoporosis Fracture Risk Awareness Lacking in Postmenopausal Women

By

Postmenopausal women have little awareness of osteoporotic fracture risk and poor understanding that a fragility fracture may be indicative of osteoporosis and that it increases future fracture risk.

USPSTF Favors Osteoporosis Screening to Prevent Fracture

USPSTF Favors Osteoporosis Screening to Prevent Fracture

Screening is recommended for women aged ≥65 years and younger women who have been through menopause and are at increased risk for osteoporosis.

Alendronate May Reduce Risk for CV Events After Hip Fracture

Alendronate May Reduce Risk for CV Events After Hip Fracture

By

Use of alendronate in individuals who experience a hip fracture is associated with a reduced risk for cardiovascular mortality, myocardial infarction, and stroke.

Serotonin Levels Predict Increased Risk for Hip Fracture, Nonvertebral Osteoporotic Fracture

Serotonin Levels Predict Increased Risk for Hip Fracture, Nonvertebral Osteoporotic Fracture

By

High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

By

Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.

Higher Groin <I>C Avidum</I> Colonization in Obese Patients After Hip Arthroplasty

Higher Groin C Avidum Colonization in Obese Patients After Hip Arthroplasty

By

Researchers assessed the incidence of Cutibacterium avidum infection in patients following primary hip arthroplasty.

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

By

Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.

Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits

Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits

By

Negative effects of 2-hour glucose was pronounced at the cortical-bone-dominant sites in women.

Prolia Approved for Glucocorticoid-Induced Osteoporosis

Prolia Approved for Glucocorticoid-Induced Osteoporosis

By

The FDA has approved use of Prolia for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.

Effects of the 2 Types of Anorexia Nervosa on Bone Metabolism

Effects of the 2 Types of Anorexia Nervosa on Bone Metabolism

By

Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

By

An osteoporosis treatment may have a positive effect on human hair follicles from those undergoing hair transplantation surgery.

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

By

The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).

Subclinical Thyroid Dysfunction Not Associated With Hip Fracture Risk in Older Men

Subclinical Thyroid Dysfunction Not Associated With Hip Fracture Risk in Older Men

By

Findings do not support a role for subclinical thyroid dysfunction as a biomarker for bone-related outcomes in older men.

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

By

Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.

Fracture Type Varies for Women With Anorexia and Oligo-Amenorrheic Athletes

Fracture Type Varies for Women With Anorexia and Oligo-Amenorrheic Athletes

By

A high stress fracture rate in oligo-amenorrheic athletes, who have whole body, less head and hip, areal bone mineral density (BMD) measures comparable to those of control patients, indicates that BMD in these women may need to be even higher to avoid fractures.

Hip Fracture Risk May Be Overestimated in Type 2 Diabetes

Hip Fracture Risk May Be Overestimated in Type 2 Diabetes

By

Researchers found that estimation of hip fracture risk without accounting for death as a competing event results in an overestimation of fracture risk.

Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis

Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis

By

Sciatic nerve block may represent an effective complement to femoral nerve block for total knee arthroplasty.

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

By

The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.

Diabetes Does Not Alter Anti-osteoporotic Treatment Response

Diabetes Does Not Alter Anti-osteoporotic Treatment Response

By

Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.

Sign Up for Free e-newsletters